Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price target of $13, up from $8.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune Group’s FDA Resubmission for RP1 Accepted
- Replimune upgraded to Neutral from Underweight at JPMorgan
- Replimune upgraded to Neutral at JPMorgan after BLA resubmission accepted
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Midday Fly By: AWS hit by outage, Kering sells beauty unit